

Updated: 03/13/2024

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE & REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>MDS</u>	NHLBI-MDS NCT02775383	The National Myelodysplastic Syndromes Natural History Study	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>SMOKING CESSATION</u>	A211901 NCT05008848	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>MULTICANCER EARLY DETECTION</u>	Alliance A212102 NCT05334069	Blinded Reference Set for Multicancer Early Detection Blood Tests	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>BREAST GASTRIC/ABDOMINAL THORACIC</u>	iCaRe ²	Integrated Cancer Repository for Cancer Research	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>LUNG NSCLC</u>	E4512 NCT02201992	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>LUNG NSCLC</u>	Alliance A151216 NCT02194738	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>LUNG ES-SCLC</u>	NRG-LU007 NCT04402788	Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>BREAST PREMENOPAUSAL</u>	S2010 NCT05568472	Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer. ASPEN Study	Ellie G. 218-249-5005 whiteside@slhduluth.com
<u>BREAST HER2+</u>	NRG-BR008 NCT05705401	Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (HERO)	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>Breast HER2+</u>	Alliance A011801 NCT04457596	T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>Colon Stage II/III BRAF V600E</u>	Alliance A022004 NCT05710406	Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	Cade M. 218-249-5647 whiteside@slhduluth.com

<u>PROSTATE</u>	NRG-GU010 NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>PROSTATE</u>	NRG-GU013 NCT05946213	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>SKIN</u>	ECOG EA6174 NCT03712605	Pembrolizumab compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>PANCREAS</u>	EA2192 NCT04858334	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>UROTHELIAL</u>	A032002 NCT04936230	Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)	Cade M. 218-249-5647 whiteside@slhduluth.com
<u>NSCLC</u>	PACIFIC-4 NCT03833154	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/ROG-3515) or Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation	Jessica L. RN, 218-249-5581 Charity G. RN, 218-249-5177 whiteside@slhduluth.com
<u>NSCLC</u>	PACIFIC-9 NCT05221840	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab or Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	Jessica L. RN, 218-249-5581 Charity G. RN, 218-249-5177 whiteside@slhduluth.com
<u>NSCLC</u>	AVANZAR NCT05687266	Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations vs standard care with pembrolizumab in combination with platinum-based chemotherapy	Jessica L. RN, 218-249-5581 Charity G. RN, 218-249-5177 whiteside@slhduluth.com
<u>LEUKEMIA</u>	ReVenG NCT04895436	Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)	Jessica L. RN, 218-249-5581 Charity G. RN, 218-249-5177 whiteside@slhduluth.com
<u>SOLID TUMORS WITH BRAF ALTERATIONS</u>	FORE8394 MCT02428712	A phase 2 trial to assess the efficacy and safety of plixorafenib, an inhibitor of BRAF class I and II alterations, in patients with BRAF alterations	Jessica L. RN, 218-249-5581 Charity G. RN, 218-249-5177 whiteside@slhduluth.com